Citigroup Maintains Neutral on Insulet, Raises Price Target to $172

Benzinga Newsdesk www.benzinga.com Positive 70.8%

Neg 0% Neu 0% Pos 70.8%

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $165 to $172.